MET and non-small cell lung carcinoma: The impact of BH-3 mimetics on RTKi resistance in neuroblastoma remains unexplored, but BH-3 mimetics enhanced MET inhibition by crizotinib in glioblastoma PDX [282] and ALK inhibition by lorlatinib in NSCLC xenografts [275].